-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the US FDA announced that it has accelerated the approval of the anti-PD-1 antibody Jemperli (dostarlimab) developed by GlaxoSmithKline (GSK) to treat patients with relapsed or advanced endometrial cancer.
Endometrial cancer is the sixth most common cancer among women in the world.
Jemperli is a humanized anti-PD-1 monoclonal antibody.
The safety and effectiveness of Jemperli are supported by a single-arm, multi-cohort clinical trial.
Reference materials:
[1] FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.